Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The U.K.-based drugmaker became the second to strike a deal with the Trump administration as part of the president's push to rein in U.S. drug prices. -
Patients who want a deeper discount on obesity meds than compounding pharmacies can offer are turning to the gray market, where they buy the raw active ingredient from China and prepare it themselves.
-
President Trump on Tuesday announced a deal with Pfizer to sell its drugs directly to consumers at discounted prices. They'll be available through a website operated by the federal government.
-
The Trump administration says it is making deals with drug companies to lower prices U.S. consumers pay for medicines. But key details are missing on how the initiative would work. -
The Trump administration sent letters this summer to 17 makers of name-brand drugs pushing them to lower prices to align them with what other countries pay. The companies had 60 days to "step up."
-
A law firm appealing a stalled case against Tylenol's maker, Kenvue, says people are calling to join the suit, alleging the painkiller caused autism in children whose mothers took it during pregnancy. -
President Trump's announcement this week linking Tylenol with autism could play a role in ongoing legal cases against the company that makes it.
-
It's been a confusing and fast-changing couple of months for rules about getting a COVID shot. It should be a little easier now, after a panel of vaccine advisers met last week. -
Though the FDA narrowed criteria for the shots, many people still want them, to avoid illness and protect vulnerable family members. Some are turned down at the pharmacy or have to jump through hoops. -
As coverage of this year's crop of COVID boosters hangs in the balance under Robert F. Kennedy Jr.'s leadership, what is the vaccine supply situation this year?
